InvestorsHub Logo
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

Re: Jake2234 post# 2441

Monday, 04/03/2023 5:53:38 PM

Monday, April 03, 2023 5:53:38 PM

Post# of 3013
If EDP-235 advances to phase-3, ENTA will likely seek to show non-inferiority to Paxlovid, which ought to be an achievable goal.

There is no FDA requirement that a COVID drug has to show any particular result for viral load or IVA to get approval.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News